Shanghai and Shenzhen stock market announcement on August 21

2020 “Yinhua Fund Cup” Sina bank financial planner competition, hot registration. From now on to September 7, you will receive free gift packages worth more than 700 yuan from Guan Qingyou, Luo Yuanshang, Chen Kaifeng and Jian Qi. < p > < p > < p > the trading day financial Morning Post has been updated, and the trading volume is less than 900 billion yuan. What are the concerns of the market? How should investors cope with the market sentiment ebbing again? Please listen to the morning post for details. < p > < p > Fosun Pharmaceutical (600196) announced on the evening of August 20 that the third batch of national drugs will be selected for centralized procurement of five drugs, including febuxostat tablets, quetiapine fumarate tablets, pivastatin calcium tablets, ethambutol hydrochloride tablets and memantine hydrochloride tablets. If the subsequent signing and implementation of the procurement contract, will be conducive to further expand the sales scale of related products, improve market share. HongRi Pharmaceutical (300026) announced on the evening of August 20 that the company participated in the third batch of centralized drug procurement organized by the state. The company’s product moxifloxacin hydrochloride and sodium chloride injection (trade name: enrotai) participated in the centralized procurement and won the bid. < p > < p > Shanghai Pharmaceutical (601607) announced on the evening of August 20 that the company’s Xinyi balance, Shangyao Chinese and Western medicine, and Shangyao Changyao participated in the bidding for the third batch of national centralized drug procurement. According to the new registration classification of chemical drugs, the generic drugs of metformin hydrochloride tablets (0.25g), Ambroxol Hydrochloride Capsules (30mg), ibuprofen sustained-release capsules (0.3g), dexzopiclone tablets (3mg), fluoxetine hydrochloride capsules (20mg) and captopril tablets (12.5mg, 25mg) approved according to the new registration of chemical drugs. The total sales revenue of the above six varieties in 2019 is about 162 million yuan. < p > < p > China Resources Shuanghe (600062) announced on the evening of August 20 that Wanhui Shuanghe and China Resources SECCO, the wholly-owned subsidiaries, have passed the evaluation of generic drug quality and efficacy consistency by the State Drug Administration of China, including metformin hydrochloride sustained-release tablets (0.5g), valsartan capsules (80mg), finasteride tablets (5mg), and weigliptin tablets (50mg), which are planned to be selected for the third batch of national drug concentration purchase. Haizheng Pharmaceutical (600267) announced on the evening of August 20 that the company’s products glucosamine sulfate capsules, anastrozole tablets, letrozole tablets and ticagrelor tablets are planned to win the bid for the third batch of national centralized drug procurement. Baiyunshan (600332) announced on the evening of August 20 that memantine hydrochloride tablets and ciprofloxacin hydrochloride tablets were to be selected as the third batch of national drug centralized procurement. Ciprofloxacin hydrochloride tablets to be selected this time have not been produced and sold in 2019 and the first half of 2020; memantine hydrochloride tablets obtained the drug registration approval in September 2019, and is currently in trial production stage. Wuzhong (600200) announced on the evening of the 20th that Suzhou pharmaceutical factory affiliated to the company participated in the bidding work of the third batch of national centralized drug procurement organized by the joint procurement office. Trimetazidine hydrochloride tablets (20mg), which has passed the quality and efficacy consistency evaluation of generic drugs by the State Drug Administration of China, has been purchased by Suzhou pharmaceutical factory. The proposed product trimetazidine hydrochloride tablets (20mg) will have a sales revenue of about 28.72 million yuan in 2019, accounting for 1.36% of the company’s operating revenue in 2019. Qianjin Xiangjiang Pharmaceutical Co., Ltd. (600479) announced on the evening of August 20 that Qianjin Xiangjiang Pharmaceutical Co., Ltd., the holding subsidiary of the company, had participated in the bidding for centralized procurement of national drugs. Qianjin Xiangjiang Pharmaceutical Co., Ltd. had purchased valsartan capsules, a generic drug evaluated by the State Drug Administration on the quality and efficacy of generic drugs. The proposed bid winning price was 8.63 yuan / 36 capsules / box; the number of bids to be won was 8.63 yuan / 36 capsules / box Quantity: 88 million capsules. The sales revenue of the product in 2019 is 175 million yuan, accounting for 4.95% of the company’s revenue in 2019. On the evening of August 20, connexin (600572) announced that tamsulosin hydrochloride sustained-release capsules, finasteride tablets and ibuprofen granules, which have passed the quality and efficacy consistency evaluation of generic drugs by the State Food and drug administration, have participated in the bidding for the third batch of national centralized drug procurement. After the bid opening and bid evaluation of the joint procurement office, tamsulosin hydrochloride sustained-release capsules and finasteride tablets were purchased in batches. In the evening of August 20, Jianmin group (600976) announced that the company’s wholly-owned subsidiary yekai Thailand pharmaceutical product levetiracetam oral solution was to be selected for the third batch of national drug centralized procurement. In April 2020, the company obtained the drug registration approval document of levetiracetam oral solution approved and issued by the State Food and drug administration. Up to now, the product has not been sold, and the product to be selected is expected to be selected The revenue of the selected quantity is 11.93 million yuan, accounting for 1% of the company’s pharmaceutical industry income in 2019. Wan Bang de (002082) announced on the evening of August 20 that wanbond Pharmaceutical Co., Ltd. had participated in the bidding of the third batch of national drug centralized procurement, and the generic drug clozapine tablets which had obtained consistency evaluation were purchased in the next centralized procurement. This bid will be conducive to wanbond pharmaceutical to give full play to the advantages of integrated production of clozapine raw materials and preparations. Wanbond pharmaceutical has been fully prepared for production, which can ensure the market supply of raw materials and tablets within the bidding period. In the evening of August 20, Jingxin Pharmaceutical (002020) announced that sertraline hydrochloride tablets and pivastatin calcium dispersible tablets, which had passed the quality and efficacy consistency evaluation of generic drugs, were to be selected in the bidding of the third batch of drugs organized by the state. In the evening of August 20, Changjiang health (002435) announced that omeprazole enteric coated capsules (20mg / capsule) of Hailing Pharmaceutical Co., Ltd., which has passed the consistency evaluation, is to be selected in the third batch of bidding for centralized drug procurement organized by the state. Leshan Electric Power (600644) announced on the evening of August 20 that due to the flood situation, part of the company’s office plants and production sites had serious water seepage, and several power supply lines and station areas were shut down, affecting the normal power supply of some power users in the network, and some power stations in the network were temporarily shut down. Up to now, the company has restored power supply to most of the power users in the network, and the power generation stations in the network have basically resumed power generation. Meanwhile, the company’s asset damage has been reported to the insurance company. In this disaster, the company has no casualties, and the amount of asset loss cannot be accurately determined. Jinmo Co., Ltd. announced on the evening of August 20 that the company disclosed on August 7 that due to the sudden rainstorm in Jindui mining area, some roads and tailings transportation pipelines were damaged, resulting in the temporary shutdown of Baihualing Concentrator and 30mudi concentrator of mining and metallurgy branch (Jindui mining area). Through active repair, Baihualing Concentrator and 30mudi concentrator have resumed production since August 20. The natural disaster only affected the molybdenum concentrate output of the company’s subordinate mining and metallurgy branch. After calculation, it is estimated that the total profit will be reduced by more than 7 million yuan. Other subsidiaries and follow-up series products have not been affected, and the overall impact on the company’s production, operation and financial situation is small. < p > < p > Guidong electric power (600310) has been trading for two consecutive days. The company announced on the evening of August 20 that the company’s production and operation are normal at present, and the production and operation situation has not changed significantly. Up to now, the river basin of the company’s hydropower plant is not affected by heavy rainfall. The company completed 944 million kWh (including small hydropower) in the first half of the year, a decrease of 23.62% over the same period of last year. Guidong electric power also disclosed a semi annual report, with a net profit loss of 54.61 million yuan in the first half of the year and a profit of 160 million yuan in the same period of last year. Jiangshan Co., Ltd. (600389) recorded two trading limit boards in the past three trading days. The company announced on the evening of August 20 that the company’s current production and operation situation was normal and the prices of main products were stable. Recently, a flood occurred in Leshan City, Sichuan Province, which affected some key glyphosate production enterprises and led to the periodic shutdown of some glyphosate production lines. However, with the gradual resumption of production of these enterprises, the tight supply situation will be gradually alleviated. At the same time, in view of the current off-season demand for glyphosate, the impact on the price of glyphosate is still uncertain, so the performance of the company is uncertain influence. In the first half of the year, the company’s revenue was 573 million yuan, a year-on-year increase of 368.65%; the net profit was 308 million yuan, an increase of 923.3%. The basic earnings per share is 5.25 yuan. The company plans to pay a cash dividend of 15 yuan per 10 shares. The novel coronavirus 2019-nCOV nucleic acid reagents were successfully developed at the first time during the reporting period. At the same time, the company overcome the difficulties of resuming production, limiting raw materials and upgrading production capacity during the new crown epidemic situation, and quickly realized the rapid increase of production capacity, thus achieving a major breakthrough in the overall performance of the first half of the year. In the first half of the year, the company’s revenue was 8.043 billion yuan, with a year-on-year increase of 41%; and the net profit was 900 million yuan, with a year-on-year increase of 1206%. The company successfully completed the acquisition of Beijing howay and sipico in 2019. The company increased the layout of CMOS image sensor field in the main business, which made the overall technical level of semiconductor design of the company rapidly improved, and brought high-quality customer resources in the fields of smart phones, security, automobile, medical and other fields for the company, and the company’s profit level was greatly improved. Li Bang instrument (300206) disclosed its semi annual report on the evening of August 20. In the first half of the year, the company realized operating revenue of 1.278 billion yuan, with a year-on-year increase of 135.26%, and net profit of 472.49% to 473 million yuan. During the epidemic period, thanks to the company’s continuous R & D investment and core competitive advantages formed by international development over the years, as well as the timely response of the group’s supply chain and marketing system, the shipment volume of medical equipment directly related to the epidemic situation increased rapidly, thus promoting the company’s performance in the first half of the year. Zhangze electric power (000767) disclosed the semi annual report on the evening of August 20. In the first half of the year, the company realized operating revenue of 5.367 billion yuan, a decrease of 8.06% compared with the same period of last year; the net profit was 115 million yuan, with a year-on-year increase of 208.86%; and the basic earnings per share was 0.0375 yuan. Wantai biological (603392) disclosed its semi annual report on the evening of August 20. In the first half of the year, the company’s revenue was 844 million yuan, up 61.13% year-on-year, and its net profit was 244 million yuan, with a year-on-year increase of 186.73%. During the reporting period, the company actively researched and developed a series of new crown diagnosis products, and worked overtime to produce new crown related diagnostic reagents, diagnostic instruments and other anti epidemic products, and supported the anti epidemic work with practical actions. The company is fully prepared for the production and market access of domestic bivalent HPV vaccine. The first batch of domestic bivalent cervical cancer vaccine will be launched in May according to the plan. The main business of vaccine has become another important guarantee for the company’s income. Hengrun shares (603985) disclosed the semi annual report on the evening of August 20. In the first half of the year, the company’s revenue was 1.05 billion yuan, up 65.17% year-on-year, and the net profit was 178 million yuan, with a year-on-year increase of 179.21%. The company plans to pay 2 yuan for every 10 shares. During the reporting period, the company’s main business income was 940 million yuan, with a year-on-year increase of 71.60%. Among them, the domestic sales revenue was 753 million yuan, with a year-on-year increase of 131.50%, which was mainly benefited from the rapid development of domestic wind power market and the continuous rush to install; the export revenue was 187 million yuan, a year-on-year decrease of 16.10%. Hongta securities (601236) disclosed its semi annual report on the evening of August 20. In the first half of the year, the company’s revenue was 2.456 billion yuan, with a year-on-year growth of 226.21%; the net profit was 780 million yuan, with a year-on-year increase of 167.1%. During the reporting period, the company’s securities brokerage business achieved an income of 99.99 million yuan, with a year-on-year increase of 3.79%; the income of securities investment business reached 1.273 billion yuan, with a year-on-year increase of 147.10%; the income of asset management business was 44.46 million yuan, with a year-on-year increase of 400.77%. < p > < p > Haier Biology (688139) disclosed its semi annual report on the evening of August 20,